- Bausch Health Canada announced that Siliq (brodalumab) is now reimbursed under Alberta’s public drug plan for eligible patients with moderate to severe plaque psoriasis who meet applicable criteria.
- Siliq is indicated for adults with moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy. It has been available in Canada since 2018.
- Alberta’s decision expands Siliq’s public coverage nationwide, with British Columbia now the only province where it remains without public drug plan coverage.
- The reimbursement gives eligible Albertans another treatment option for a chronic condition that can significantly affect physical comfort, emotional well-being and daily functioning, supporting more individualized care.
Takeaways:
Siliq’s listing under Alberta’s public drug plan expands brodalumab’s public coverage across Canada, leaving only British Columbia without provincial reimbursement and improving access for eligible patients with moderate to severe plaque psoriasis who need systemic therapy or phototherapy. This move strengthens Bausch Health’s competitive position in the Canadian psoriasis biologics market by adding another reimbursed option alongside other IL‑17 and IL‑23 inhibitors, potentially increasing uptake among dermatologists and patients who prefer an IL‑17 receptor–targeting mechanism.
Source: CA Newswire
